-+ 0.00%
-+ 0.00%
-+ 0.00%

Structure Therapeutics Initiates First-In-Human Phase 1 Clinical Study Of ACCG-2671, Lead Oral Small Molecule Amylin Receptor Agonist For Obesity Treatment

Benzinga·12/17/2025 13:38:19
Listen to the news

Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that it has initiated a first-in-human Phase 1 clinical study of ACCG-2671, the company's lead oral small molecule amylin receptor agonist for the treatment of obesity. ACCG-2671 was designed via the company's next generation structure-based drug discovery platform to harness the established metabolic benefits of amylin biology in an oral, once-daily small molecule, with the potential to improve scalability, combinability, and patient access.